Trials / Completed
CompletedNCT00408603
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 183 (actual)
- Sponsor
- Sunesis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
Detailed description
Other objectives of this study are to evaluate Progression-free survival and measure CA-125 response rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Voreloxin Injection | All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable. |
Timeline
- Start date
- 2006-12-20
- Primary completion
- 2010-06-09
- Completion
- 2010-06-09
- First posted
- 2006-12-07
- Last updated
- 2017-07-27
- Results posted
- 2017-06-28
Locations
20 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00408603. Inclusion in this directory is not an endorsement.